Quest Diagnostics Stock News

Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NY...

SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ --  Quest Diagnostics  (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.

GRAIL's Galleri   Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience  MENLO PARK, Calif. and SECAUCUS, N.J.

SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.

Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day.

Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conference Call Participants Kevin Caliendo - UBS Patrick Donnelley - Citi Michael Cherny - Leerink Partners Joanna Zhou - Evercore ISI Pito Chickering - Deutsche Bank David Westenberg - Piper Sandler ...

Quest Diagnostics (DGX 6.36%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18.

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported di...